What makes $Moderna (MRNA.US)$ Has the stock price increased by more than 200% since this year? Not only was it included in the S&P 500 constituent stock, but its market capitalization also surpassed 100 billion US dollars, surpassing it in one fell swoop $GlaxoSmithKline (GSK.US)$ It broke the original pattern of the Big Four vaccine companies. Today we're going to talk about Modena.
The COVID-19 pandemic swept the world last year, and telecommuting became a new way for everyone to work, and the new way of working made ZOOM a big hit. The introduction of the COVID-19 vaccine this year has also given rise to a boom in vaccine stocks. The biotech company Modena originally used mRNA technology to develop drugs for infectious diseases, but when developing COVID-19 vaccines, they found that the results were very good. Not only was the development speed faster than traditional inactivated vaccines, but the protection rate was also very high, as high as 94.1%.
The COVID-19 vaccine developed by BioNTech, another biotech company that also has mRNA technology at its core, has a protection rate of 95.3%, bringing cutting-edge mRNA technology into the public eye.
After the vaccine was proven to be effective, Modena began mass production at the end of last year, and the first quarter of this year was also the beginning of Modena's commercialization. In the first quarter, Modena shipped 102 million doses of the COVID-19 vaccine, revenue was 1.9 billion US dollars, and net profit was 1.2 billion US dollars. How profitable is this? GlaxoSmithKline, one of the Big Four vaccine companies mentioned earlier, had a net profit of 1.26 billion US dollars in the first quarter of this year. As a company just beginning to commercialize, Modena's net profit for the first quarter...